目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. End-use
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. End-use outlook
2.2.3. Regional outlook
2.3. Competitive Insights

Chapter 3. Spine Biologics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Growing prevalence of spine deformities
3.2.1.2. Rising technological advancements in spine biologics
3.2.1.3. Increasing geriatric population
3.2.2. Market restraint analysis
3.2.2.1. High cost of bone grafts
3.2.2.2. Stringent regulatory requirements for approval of biologics
3.3. Spine Biologics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
3.3.3. Pricing Analysis

Chapter 4. Spine Biologics Market: Product Estimates & Trend Analysis
4.1. Product Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Spine Biologics Market by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Spinal Allografts
4.4.1.1. Spinal Allografts Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2. Machined Bones Allograft
4.4.1.2.1. Machined Bones Allograft Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3. Demineralized Bone Matrix
4.4.1.3.1. Demineralized Bone Matrix Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Bone Graft Substitutes
4.4.2.1. Bone Graft Substitutes Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.2. Bone Morphogenetic Proteins
4.4.2.2.1. Bone Morphogenetic Proteins Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.3. Synthetic Bone Grafts
4.4.2.3.1. Synthetic Bone Grafts Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Cell-based Matrix
4.4.3.1. Cell-based Matrix Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Spine Biologics Market: End-use Estimates & Trend Analysis
5.1. End-use Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Spine Biologics Market by End-use Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Hospitals
5.4.1.1. Hospitals Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Outpatient Facilities
5.4.2.1. Outpatient Facilities Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Spine Biologics Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2023 & 2030
6.2. Regional Market Dashboard
6.3. Global Regional Market Snapshot
6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.5. North America
6.5.1. U.S.
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework
6.5.1.3. Competitive scenario
6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.5.2. Canada
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework
6.5.2.3. Competitive scenario
6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Europe
6.6.1. UK
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework
6.6.1.3. Competitive scenario
6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.6.2. Germany
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework
6.6.2.3. Competitive scenario
6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.6.3. France
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework
6.6.3.3. Competitive scenario
6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.6.4. Italy
6.6.4.1. Key country dynamics
6.6.4.2. Regulatory framework
6.6.4.3. Competitive scenario
6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.6.5. Spain
6.6.5.1. Key country dynamics
6.6.5.2. Regulatory framework
6.6.5.3. Competitive scenario
6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.6.6. Norway
6.6.6.1. Key country dynamics
6.6.6.2. Regulatory framework
6.6.6.3. Competitive scenario
6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.6.7. Sweden
6.6.7.1. Key country dynamics
6.6.7.2. Regulatory framework
6.6.7.3. Competitive scenario
6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.6.8. Denmark
6.6.8.1. Key country dynamics
6.6.8.2. Regulatory framework
6.6.8.3. Competitive scenario
6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Asia Pacific
6.7.1. Japan
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework
6.7.1.3. Competitive scenario
6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.7.2. China
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework
6.7.2.3. Competitive scenario
6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.7.3. India
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework
6.7.3.3. Competitive scenario
6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.7.4. Australia
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework
6.7.4.3. Competitive scenario
6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.7.5. South Korea
6.7.5.1. Key country dynamics
6.7.5.2. Regulatory framework
6.7.5.3. Competitive scenario
6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.7.6. Thailand
6.7.6.1. Key country dynamics
6.7.6.2. Regulatory framework
6.7.6.3. Competitive scenario
6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
6.8. Latin America
6.8.1. Brazil
6.8.1.1. Key country dynamics
6.8.1.2. Regulatory framework
6.8.1.3. Competitive scenario
6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.8.2. Mexico
6.8.2.1. Key country dynamics
6.8.2.2. Regulatory framework
6.8.2.3. Competitive scenario
6.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
6.8.3. Argentina
6.8.3.1. Key country dynamics
6.8.3.2. Regulatory framework
6.8.3.3. Competitive scenario
6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.9. MEA
6.9.1. South Africa
6.9.1.1. Key country dynamics
6.9.1.2. Regulatory framework
6.9.1.3. Competitive scenario
6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
6.9.2. Saudi Arabia
6.9.2.1. Key country dynamics
6.9.2.2. Regulatory framework
6.9.2.3. Competitive scenario
6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
6.9.3. UAE
6.9.3.1. Key country dynamics
6.9.3.2. Regulatory framework
6.9.3.3. Competitive scenario
6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
6.9.4. Kuwait
6.9.4.1. Key country dynamics
6.9.4.2. Regulatory framework
6.9.4.3. Competitive scenario
6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2023
7.3.4. Stryker
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. NuVasive, Inc.
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. Orthofix
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. DePuy Synthes (Johnson & Johnson)
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Exactech, Inc.
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Zimmer Biomet
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Arthrex, Inc.
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
7.3.11. Medtronic
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Product benchmarking
7.3.11.4. Strategic initiatives
7.3.12. Organogenesis Inc.
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Product benchmarking
7.3.12.4. Strategic initiatives
7.3.13. Kuros Biosciences.
7.3.13.1. Company overview
7.3.13.2. Financial performance
7.3.13.3. Product benchmarking
7.3.13.4. Strategic initiatives

List of Tables
Table 1 List of abbreviation
Table 2 North America spine biologics market, by region, 2018 - 2030 (USD Million)
Table 3 North America spine biologics market, by product, 2018 - 2030 (USD Million)
Table 4 North America spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 5 U.S. spine biologics market, by product, 2018 - 2030 (USD Million)
Table 6 U.S. spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 7 Canada spine biologics market, by product, 2018 - 2030 (USD Million)
Table 8 Canada spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 9 Europe spine biologics market, by region, 2018 - 2030 (USD Million)
Table 10 Europe spine biologics market, by product, 2018 - 2030 (USD Million)
Table 11 Europe spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 12 Germany spine biologics market, by product, 2018 - 2030 (USD Million)
Table 13 Germany spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 14 UK spine biologics market, by product, 2018 - 2030 (USD Million)
Table 15 UK spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 16 France spine biologics market, by product, 2018 - 2030 (USD Million)
Table 17 France spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 18 Italy spine biologics market, by product, 2018 - 2030 (USD Million)
Table 19 Italy spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 20 Spain spine biologics market, by product, 2018 - 2030 (USD Million)
Table 21 Spain spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 22 Denmark spine biologics market, by product, 2018 - 2030 (USD Million)
Table 23 Denmark spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 24 Sweden spine biologics market, by product, 2018 - 2030 (USD Million)
Table 25 Sweden spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 26 Norway spine biologics market, by product, 2018 - 2030 (USD Million)
Table 27 Norway spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 28 Asia Pacific spine biologics market, by region, 2018 - 2030 (USD Million)
Table 29 Asia Pacific spine biologics market, by product, 2018 - 2030 (USD Million)
Table 30 Asia Pacific spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 31 China spine biologics market, by product, 2018 - 2030 (USD Million)
Table 32 China spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 33 Japan spine biologics market, by product, 2018 - 2030 (USD Million)
Table 34 Japan spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 35 India spine biologics market, by product, 2018 - 2030 (USD Million)
Table 36 India spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 37 South Korea spine biologics market, by product, 2018 - 2030 (USD Million)
Table 38 South Korea spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 39 Australia spine biologics market, by product, 2018 - 2030 (USD Million)
Table 40 Australia spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 41 Thailand spine biologics market, by product, 2018 - 2030 (USD Million)
Table 42 Thailand spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 43 Latin America spine biologics market, by product, 2018 - 2030 (USD Million)
Table 44 Latin America spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 45 Brazil spine biologics market, by product, 2018 - 2030 (USD Million)
Table 46 Brazil spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 47 Mexico spine biologics market, by product, 2018 - 2030 (USD Million)
Table 48 Mexico spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 49 Argentina spine biologics market, by product, 2018 - 2030 (USD Million)
Table 50 Argentina spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 51 MEA spine biologics market, by region, 2018 - 2030 (USD Million)
Table 52 MEA spine biologics market, by product, 2018 - 2030 (USD Million)
Table 53 MEA spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 54 South Africa spine biologics market, by product, 2018 - 2030 (USD Million)
Table 55 South Africa spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 56 Saudi Arabia spine biologics market, by product, 2018 - 2030 (USD Million)
Table 57 Saudi Arabia spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 58 UAE spine biologics market, by product, 2018 - 2030 (USD Million)
Table 59 UAE spine biologics market, by end-use, 2018 - 2030 (USD Million)
Table 60 Kuwait spine biologics market, by product, 2018 - 2030 (USD Million)
Table 61 Kuwait spine biologics market, by end-use, 2018 - 2030 (USD Million)

List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Spine biologics market: market outlook
Fig. 14 Spine biologics competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Penetration and growth prospect mapping
Fig. 18 Industry value chain analysis
Fig. 19 Spine biologics market driver impact
Fig. 20 Spine biologics market restraint impact
Fig. 21 Spine biologics market strategic initiatives analysis
Fig. 22 Spine biologics market: Product movement analysis
Fig. 23 Spine biologics market: Product outlook and key takeaways
Fig. 24 Spinal allografts market estimates and forecast, 2018 - 2030
Fig. 25 Machined bones allograft market estimates and forecast, 2018 - 2030
Fig. 26 Demineralized bone matrix market estimates and forecast, 2018 - 2030
Fig. 27 Bone graft substitutes market estimates and forecast, 2018 - 2030
Fig. 28 Bone morphogenetic proteins market estimates and forecast, 2018 - 2030
Fig. 29 Synthetic bone grafts market estimates and forecast, 2018 - 2030
Fig. 30 Cell-based matrix market estimates and forecast, 2018 - 2030
Fig. 31 Spine biologics market: end-use movement analysis
Fig. 32 Spine biologics market: end-use outlook and key takeaways
Fig. 33 Outpatient facilities market estimates and forecasts, 2018 - 2030
Fig. 34 Hospitals market estimates and forecasts,2018 - 2030
Fig. 35 Global spine biologics market: Regional movement analysis
Fig. 36 Global spine biologics market: Regional outlook and key takeaways
Fig. 37 Global spine biologics market share and leading players
Fig. 38 North America market share and leading players
Fig. 39 Europe market share and leading players
Fig. 40 Asia Pacific market share and leading players
Fig. 41 Latin America market share and leading players
Fig. 42 Middle East & Africa market share and leading players
Fig. 43 North America, by country
Fig. 44 North America market estimates and forecasts, 2018 - 2030
Fig. 45 U.S. market estimates and forecasts, 2018 - 2030
Fig. 46 Canada market estimates and forecasts, 2018 - 2030
Fig. 47 Europe market estimates and forecasts, 2018 - 2030
Fig. 48 UK market estimates and forecasts, 2018 - 2030
Fig. 49 Germany market estimates and forecasts, 2018 - 2030
Fig. 50 France market estimates and forecasts, 2018 - 2030
Fig. 51 Italy market estimates and forecasts, 2018 - 2030
Fig. 52 Spain market estimates and forecasts, 2018 - 2030
Fig. 53 Denmark market estimates and forecasts, 2018 - 2030
Fig. 54 Sweden market estimates and forecasts, 2018 - 2030
Fig. 55 Norway market estimates and forecasts, 2018 - 2030
Fig. 56 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 57 China market estimates and forecasts, 2018 - 2030
Fig. 58 Japan market estimates and forecasts, 2018 - 2030
Fig. 59 India market estimates and forecasts, 2018 - 2030
Fig. 60 Thailand market estimates and forecasts, 2018 - 2030
Fig. 61 South Korea market estimates and forecasts, 2018 - 2030
Fig. 62 Australia market estimates and forecasts, 2018 - 2030
Fig. 63 Latin America market estimates and forecasts, 2018 - 2030
Fig. 64 Brazil market estimates and forecasts, 2018 - 2030
Fig. 65 Mexico market estimates and forecasts, 2018 - 2030
Fig. 66 Argentina market estimates and forecasts, 2018 - 2030
Fig. 67 Middle East and Africa market estimates and forecasts, 2018 - 2030
Fig. 68 South Africa market estimates and forecasts, 2018 - 2030
Fig. 69 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 70 UAE market estimates and forecasts, 2018 - 2030
Fig. 71 Kuwait market estimates and forecasts, 2018 - 2030
Fig. 72 Market share of key market players- Spine biologics market